Similarly, another study has provided an evidence of ctDNA testing monitoring disease progression of patients with advanced NSCLC during treatment with erlotinib, and EGFR T790M mutation was detected by ctDNA testing earlier than clinically evident disease (60). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.